Sage therapeutics, inc. (SAGE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Total revenue

8,689

6,868

94,908

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating costs and expenses:
Cost of goods sold

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

346,027

368,815

366,370

339,314

319,235

282,107

244,193

227,427

214,347

210,277

201,390

172,179

142,375

120,756

99,128

87,531

80,038

69,357

57,926

47,049

32,827

24,100

18,563

15,816

0

0

0

Selling, general and administrative

331,988

345,777

336,343

301,534

256,474

201,404

145,266

107,660

79,447

62,878

57,696

50,598

44,554

39,407

33,268

30,883

28,429

25,293

20,474

16,739

12,090

9,710

7,404

5,336

0

0

0

Total operating costs and expenses

678,585

714,992

702,894

640,892

575,709

483,511

389,459

335,087

293,794

273,155

259,086

222,777

186,929

160,163

132,396

118,414

108,467

94,650

78,400

63,788

44,917

33,810

25,967

21,152

0

0

0

Loss from operations

-669,896

-708,124

-697,713

-639,281

-484,971

-393,238

-299,459

-245,087

-293,794

-273,155

-259,086

-222,777

-186,929

-160,163

-132,396

-118,414

-108,467

-94,650

-78,400

-63,788

-44,917

-33,810

-25,967

-21,152

0

0

0

Interest income, net

26,091

27,804

27,740

26,330

23,247

20,334

15,526

10,386

5,921

3,099

2,551

2,149

1,743

1,211

779

557

332

178

118

66

0

-

0

0

-

-

-

Other income, net

233

82

0

18

34

22

18

-15

-67

-64

-65

-49

-36

-35

-31

-30

-32

-23

-11

-10

0

-

0

0

-

-

-

Net loss

-643,572

-680,238

-669,973

-612,933

-461,690

-372,882

-283,915

-234,716

-287,940

-270,120

-256,600

-220,677

-185,222

-158,987

-131,648

-117,887

-108,167

-94,495

-78,294

-63,727

-44,892

-33,811

-25,969

-21,156

0

0

0

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,294

0

0

0

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-36,105

-28,263

-23,059

0

0

0

Net loss per share—basic and diluted

-2.44

-3.25

-3.48

-3.28

-3.37

-3.41

-2.63

-0.36

-1.68

-1.72

-1.97

-1.88

-1.52

-1.55

-1.15

-1.08

-0.97

-1.00

-0.84

-0.90

-0.66

7.10

-0.50

-4.57

-3.70

-2.98

-3.18

Weighted average number of common shares outstanding—basic and diluted

51,908

51,881

51,704

51,257

48,491

46,910

46,706

46,541

44,325

40,353

37,470

37,361

37,269

37,289

32,975

32,062

31,643

28,859

28,737

27,860

25,655

63,362

19,581

1,700

1,652

1,514

1,464

Comprehensive loss:
Net loss

-643,572

-680,238

-669,973

-612,933

-461,690

-372,882

-283,915

-234,716

-287,940

-270,120

-256,600

-220,677

-185,222

-158,987

-131,648

-117,887

-108,167

-94,495

-78,294

-63,727

-44,892

-33,811

-25,969

-21,156

0

0

0

Other comprehensive items:
Unrealized gain (loss) on marketable securities

-686

1,810

2,034

1,720

79

-486

-242

-78

-104

73

13

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive gain (loss)

-686

1,810

2,034

1,720

79

-486

-242

-78

-104

73

13

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-644,258

-678,428

-667,939

-611,213

-461,611

-373,368

-284,157

-234,794

-288,044

-270,047

-256,580

-220,783

-185,303

-159,089

-127,156

-114,313

0

-

0

0

-

-

-

-

-

-

-

Product Revenue [Member]
Total revenue

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Revenue [Member]
Total revenue

-

2,911

92,911

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-